Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783531 | 0.91 | HTR2C (0.79) | HTR2CHTR2AHTR2B | |
| SCHEMBL5405205 | 0.90 | HTR2C (0.74) | HTR2CHTR2AHTR2BS1PR1S1PR3 | |
| SCHEMBL6500966 | 0.89 | HTR2A (0.65) | HTR2CHTR2AHTR2B | |
| SCHEMBL5416619 | 0.89 | HTR2C (0.83) | HTR2CHTR2AHTR2BS1PR1S1PR3 | |
| SCHEMBL5410592 | 0.88 | HTR2C (0.79) | HTR2CHTR2AHTR2BS1PR1S1PR3 | |
| SCHEMBL5637117 | 0.85 | HTR2C (0.62) | HTR2CHTR2AHTR2B | |
| SCHEMBL6492559 | 0.84 | HTR2C (0.58) | HTR2CHTR2AHTR2B | |
| SCHEMBL6782509 | 0.83 | HTR2C (0.57) | HTR2CHTR2AHTR2B | |
| SCHEMBL5636323 | 0.83 | HTR2C (0.59) | HTR2CHTR2AHTR2BS1PR1S1PR3 | |
| SCHEMBL29388613 | 0.82 | HTR2C (0.62) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-6699852-B2 | ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | HTR2C 11/4885HTR2A 21/4885HTR2B 5/4885 |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | HTR2C 11/4885HTR2A 21/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.